View Older Stories View More Recent Stories

Jun 6, 2023 08:00AM MilliporeSigma Announces Proteologix as Winner of its North American Advance Biotech Grant
Jun 6, 2023 06:51AM Merck (MRK) Announces FDA Approval of New Indication for PREVYMIS for CMV Disease in High-Risk Adult Kidney Transplant Recipients
Jun 6, 2023 06:50AM U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
Jun 6, 2023 06:45AM Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
Jun 5, 2023 08:01AM Moderna (MRNA) and Merck (MRK) Announce mRNA-4157 in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Pat
Jun 3, 2023 09:00AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemothe
Jun 3, 2023 08:00AM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
Jun 1, 2023 07:03AM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Jun 1, 2023 06:45AM Merck (MRK) Announces FDA Approval of LYNPARZA Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated mCRPC
Jun 1, 2023 06:45AM FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
May 25, 2023 05:02PM Merck (MRK) Reports KEYTRUDA Plus LENVIMA Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 25, 2023 05:00PM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 23, 2023 02:45PM Merck Announces Third-Quarter 2023 Dividend
May 18, 2023 08:00AM Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
May 15, 2023 06:45AM Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
May 8, 2023 02:45PM Merck Announces Global Grants Program To Improve Access to Quality Health Care in Underserved Communities
May 1, 2023 05:24AM Merck (MRK) Provides Update on Vote on LYNPARZA Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
Apr 28, 2023 05:30PM Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
Apr 27, 2023 06:30AM Merck Announces First-Quarter 2023 Financial Results
Apr 16, 2023 12:06PM Merck's (MRK) KEYTRUDA plus chemo 'significantly' improves overall survival in binary tract cancer
Apr 16, 2023 11:00AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
Apr 16, 2023 10:17AM Merck (MRK) to acquire Prometheus Biosciences Inc. (RXDX) for $200/share
Apr 16, 2023 06:00AM Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Apr 16, 2023 06:00AM Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Apr 13, 2023 06:46AM Merck (MRK) Announces FDA Acceptance of Application for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar
Apr 13, 2023 06:45AM FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar
Apr 11, 2023 01:20PM Merck Named One of Fortune’s 2023 100 Best Companies to Work For(R)
Apr 10, 2023 05:49AM Merck (MRK) and Eisai Provide Update on Phase 3 Trials of KEYTRUDA Plus LENVIMA
Apr 10, 2023 05:48AM Moderna (MRNA) and Merck (MRK) Report MRNA-4157/V940 in Combination With Keytruda Received Prime Scheme Designation in EU
Apr 7, 2023 06:45AM Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-
Apr 3, 2023 05:01PM FDA Approves Merck’s (MRK) KEYTRUDA in Combination With Padcev for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Apr 3, 2023 05:00PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Can
Mar 30, 2023 06:45AM Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
Mar 29, 2023 04:15PM Merck (MRK) Announces FDA Converts to Full Approval Indication for KEYTRUDA for MSI-H
Mar 29, 2023 04:15PM FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMM
Mar 27, 2023 05:18PM Merck (MRK) Reports KEYTRUDA Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
Mar 27, 2023 05:15PM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Rega
Mar 27, 2023 08:00AM Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)
Mar 16, 2023 04:08PM Merck (MRK) Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial of MK-7684A
Mar 16, 2023 04:05PM Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small
Mar 10, 2023 06:45AM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
Mar 8, 2023 06:45AM Merck to Present at the Barclays 2023 Global Healthcare Conference
Mar 6, 2023 12:01PM Merck (MRK) Announces Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
Mar 6, 2023 12:01PM Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Backgroun
Mar 6, 2023 12:00PM Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
Mar 6, 2023 06:45AM Merck (MRK) Announces FDA Approval of Intramuscular Administration of MMRV Family of Vaccines
Mar 6, 2023 06:45AM US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measl
Mar 2, 2023 09:04AM Merck (MRK) and AstraZeneca (AZN) Provide Update on US Regulatory Review of LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone
Mar 2, 2023 09:00AM Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-
Mar 1, 2023 06:45AM Merck (MRK) Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS)
View More Recent Stories View Older Stories